Skip to main content

Table 1 Patients characteristics

From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

  ITT popuration (n = 90) KRAS wild type KRAS mutant
  p53 antibody p53 antibody p53 antibody
  Positive Negative Positive Negative Positive Negative
  (n = 36) (n = 54) (n = 11) (n = 31) (n = 13) (n = 13)
Gender, n (%)
Male 25(69.4) 30(55.5) 9(81.8) 16(51.6) 9(69.2) 8(61.5)
Female 11(30.5) 24(44.4) 2(18.1) 15(48.3) 4(30.7) 5(38.4)
Age
Median (range) 58.4(39–74) 60.9(39–75) 57.3(41–73) 59.8(39–71) 59.3(39–74) 61.3 (41–75)
<65, n (%) 26(72.2) 31(59.2) 8(72.7) 19(61.2) 9(69.2) 6(46.1)
65, n (%) 10(27.7) 23(42.5) 3(27.2) 12(38.7) 4(30.7) 7(53.8)
ECOG PS at base line, n (%)
  0 33(91.6) 51(94.4) 11(100) 30(96.7) 9(69.2) 12(92.3)
  1 3(8.3) 3(5.5) 0(0) 1(3.1) 3(23.0) 1(7.7)
Liver metastasis, n (%) 12(33.3) 31(57.4) 7(63.6) 19(61.2) 3(23.0) 5(38.4)
Lung metastasis, n (%) 12(33.3) 22(40.7) 5(45.4) 9(29.0) 4(30.7) 8(61.5)
Lymph node metastasis, n (%) 21(66.6) 26(48.1) 8(72.7) 17(54.8) 8(61.5) 4(30.7)
  1. ITT intention to treat, PS performance status